Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir's Reformulated Zenvia Succeeds In Confirmatory Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After battling back from a crippling FDA "approvable" letter for Zenvia, its investigational treatment for the sudden and unpredictable emotional outbursts that can accompany neurologic diseases, Avanir is buoyantly predicting a 2010 launch based on positive top-line data from the Phase III confirmatory study it conducted at the agency’s behest.

You may also be interested in...



Cash Constraints Force Industry To Retool Its Opinion Of PIPEs

Private investments in public equity help firms reach inflection points.

Avanir Divests FazaClo To Azur Pharma To Fund Zenvia Studies

Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.

Avanir Reports Positive Phase III Results For Zenvia In Diabetic Neuropathic Pain

Confirmatory Phase III trial for Zenvia in involuntary emotional expression disorder set to launch later this year.

Related Content

Topics

UsernamePublicRestriction

Register

PS004204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel